Skip to main content
Erschienen in: Annals of Hematology 11/2017

16.08.2017 | Original Article

A cross-sectional study on late taste disorders in survivors of allogeneic hematopoietic cell transplantation

verfasst von: Tomoko Sato, Takaaki Konuma, Yoriko Miwa, Nozomi Sugihara, Yukari Tsuru, Hatsuko Narita, Satomi Kiriyama, Seiko Kato, Maki Oiwa-Monna, Koji Kobayashi, Satoshi Takahashi, Arinobu Tojo

Erschienen in: Annals of Hematology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Taste disorders are one of the most common complications in patients undergoing allogeneic hematopoietic cell transplantation (HCT). They persist in some patients as a late complication 3 months or more after HCT. Therefore, we conducted a cross-sectional study to evaluate the prevalence and predictive factors of late taste disorders, with the help of a self-reporting and closed-ended questionnaire, which was distributed among 91 patients in our institute. The median age at this study was 50 (range, 25–69) years. The median follow-up period was 54 (range, 3–234) months after HCT. Taste disorders were observed in 43 patients (47%). The most frequent form of late taste disorders was reduced appetite in 18 patients (20%). The most frequent form of decline of basic taste was umami, which was observed in 12 patients (13%). Almost all taste disorders were mild in their severity. Multivariate logistic regression analyses showed that the duration of less than 1 year post HCT and the presence of oral chronic graft-versus-host disease are important risk factors for late taste disorders in survivors of HCT. These data suggested that taste disorders usually return to normal levels more than a year after HCT in most recipients.
Literatur
1.
Zurück zum Zitat Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087CrossRefPubMed Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087CrossRefPubMed
2.
Zurück zum Zitat Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A, Kemmler G et al (2012) Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manag 44:880–895CrossRef Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A, Kemmler G et al (2012) Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manag 44:880–895CrossRef
3.
Zurück zum Zitat Ruo Redda MG, Allis S (2006) Radiotherapy-induced taste impairment. Cancer Treat Rev 32:541–547CrossRefPubMed Ruo Redda MG, Allis S (2006) Radiotherapy-induced taste impairment. Cancer Treat Rev 32:541–547CrossRefPubMed
4.
Zurück zum Zitat Boer CC, Correa ME, Miranda EC, de Souza CA (2010) Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 45:705–711CrossRefPubMed Boer CC, Correa ME, Miranda EC, de Souza CA (2010) Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 45:705–711CrossRefPubMed
5.
Zurück zum Zitat Marinone MG, Rizzoni D, Ferremi P, Rossi G, Izzi T, Brusotti C (1991) Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Haematologica 76:519–522PubMed Marinone MG, Rizzoni D, Ferremi P, Rossi G, Izzi T, Brusotti C (1991) Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Haematologica 76:519–522PubMed
6.
Zurück zum Zitat Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringdén O (1992) Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 21:33–37CrossRefPubMed Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringdén O (1992) Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 21:33–37CrossRefPubMed
7.
Zurück zum Zitat Majorana A, Amadori F, Bardellini E, Campus G, Conti G, Strohmenger L et al (2015) Taste dysfunction in patients undergoing hematopoietic stem cell transplantation: clinical evaluation in children. Pediatr Transplant 19:571–575CrossRefPubMed Majorana A, Amadori F, Bardellini E, Campus G, Conti G, Strohmenger L et al (2015) Taste dysfunction in patients undergoing hematopoietic stem cell transplantation: clinical evaluation in children. Pediatr Transplant 19:571–575CrossRefPubMed
8.
Zurück zum Zitat Epstein JB, Phillips N, Parry J, Epstein MS, Nevill T, Stevenson-Moore P (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30:785–792CrossRefPubMed Epstein JB, Phillips N, Parry J, Epstein MS, Nevill T, Stevenson-Moore P (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30:785–792CrossRefPubMed
9.
Zurück zum Zitat Kano T, Kanda K (2013) Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum 40:E79–E85CrossRefPubMed Kano T, Kanda K (2013) Development and validation of a chemotherapy-induced taste alteration scale. Oncol Nurs Forum 40:E79–E85CrossRefPubMed
10.
Zurück zum Zitat Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15:367–369CrossRefPubMedPubMedCentral Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15:367–369CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956CrossRefPubMed Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956CrossRefPubMed
12.
Zurück zum Zitat Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed
13.
Zurück zum Zitat Shi HB, Masuda M, Umezaki T, Kuratomi Y, Kumamoto Y, Yamamoto T et al (2004) Irradiation impairment of umami taste in patients with head and neck cancer. Auris Nasus Larynx 31:401–406CrossRefPubMed Shi HB, Masuda M, Umezaki T, Kuratomi Y, Kumamoto Y, Yamamoto T et al (2004) Irradiation impairment of umami taste in patients with head and neck cancer. Auris Nasus Larynx 31:401–406CrossRefPubMed
14.
Zurück zum Zitat Turcott JG, Juárez-Hernández E, De la Torre-Vallejo M, Sánchez-Lara K, Luvian-Morales J, Arrieta O (2016) Changes in the detection and recognition thresholds of three basic tastes in lung cancer patients receiving cisplatin and paclitaxel and its association with nutritional and quality of life parameters. Nutr Cancer 68:241–249CrossRefPubMed Turcott JG, Juárez-Hernández E, De la Torre-Vallejo M, Sánchez-Lara K, Luvian-Morales J, Arrieta O (2016) Changes in the detection and recognition thresholds of three basic tastes in lung cancer patients receiving cisplatin and paclitaxel and its association with nutritional and quality of life parameters. Nutr Cancer 68:241–249CrossRefPubMed
15.
Zurück zum Zitat Tsutsumi R, Goda M, Fujimoto C, Kanno K, Nobe M, Kitamura Y et al (2016) Effects of chemotherapy on gene expression of lingual taste receptors in patients with head and neck cancer. Laryngoscope 126:E103–E109CrossRefPubMed Tsutsumi R, Goda M, Fujimoto C, Kanno K, Nobe M, Kitamura Y et al (2016) Effects of chemotherapy on gene expression of lingual taste receptors in patients with head and neck cancer. Laryngoscope 126:E103–E109CrossRefPubMed
16.
Zurück zum Zitat Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L et al (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37:1031–1035CrossRefPubMed Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L et al (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37:1031–1035CrossRefPubMed
17.
Zurück zum Zitat Marchesi F, Tendas A, Giannarelli D, Viggiani C, Gumenyuk S, Renzi D et al (2017) Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplant 52:154–156CrossRefPubMed Marchesi F, Tendas A, Giannarelli D, Viggiani C, Gumenyuk S, Renzi D et al (2017) Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplant 52:154–156CrossRefPubMed
18.
Zurück zum Zitat Okada N, Hanafusa T, Abe S, Sato C, Nakamura T, Teraoka K et al (2016) Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention. Support Care Cancer 24:3979–3985CrossRefPubMed Okada N, Hanafusa T, Abe S, Sato C, Nakamura T, Teraoka K et al (2016) Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention. Support Care Cancer 24:3979–3985CrossRefPubMed
Metadaten
Titel
A cross-sectional study on late taste disorders in survivors of allogeneic hematopoietic cell transplantation
verfasst von
Tomoko Sato
Takaaki Konuma
Yoriko Miwa
Nozomi Sugihara
Yukari Tsuru
Hatsuko Narita
Satomi Kiriyama
Seiko Kato
Maki Oiwa-Monna
Koji Kobayashi
Satoshi Takahashi
Arinobu Tojo
Publikationsdatum
16.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 11/2017
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3087-6

Weitere Artikel der Ausgabe 11/2017

Annals of Hematology 11/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.